B
Biobot Analytics
Analyzes city sewage to estimate opioid consumption
About Biobot Analytics
Biobot Analytics is a pioneering startup specializing in wastewater epidemiology, a field that analyzes sewage to gather public health data. The company serves a diverse range of clients, including governments, businesses, universities, and health systems. By analyzing wastewater, Biobot provides critical insights into community health trends, such as the prevalence of high-risk substances, respiratory illnesses, and foodborne diseases. This information helps clients make informed decisions to improve public health efforts and enhance community well-being.
Operating in the public health and environmental monitoring market, Biobot has positioned itself as a leader in wastewater analysis. The company’s business model revolves around offering data analysis services and insights derived from wastewater samples. Clients subscribe to Biobot’s services to receive regular reports and real-time data, which they use to track and respond to health trends within their communities.
Biobot makes money through subscription fees and service contracts with its clients. Governments and enterprises pay for ongoing monitoring and analysis, while universities and health systems might engage Biobot for specific research projects or public health initiatives. The company’s innovative approach has proven especially valuable during the COVID-19 pandemic, where wastewater analysis has been used to track the spread of the virus and inform public health responses.
In summary, Biobot Analytics transforms wastewater infrastructure into a tool for public health surveillance, providing actionable insights to a wide range of clients. By leveraging this unique data source, the company helps improve health outcomes and equity in community health.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 72.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Water Quality, Spinout, Urban Tech, Wastewater Treatment, Govtech and Civictech, Water Tech, YC W18, DT and LS
- Technology
- Hardware, Deep Tech
- Business model
- Marketplace & ecommerce
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jun 2025 | $0 | — | Hyperplane VC · Atreides Management · Valor Equity Partners | ↗ |
| EARLY VCOther financing | Sep 2024 | $30M | $120M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Biobot Analytics is 5.4K monthly website visits, up 0% over the last three months. Biobot Analytics's team grew 3.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
MIT Founders' Skills Accelerator
Forward Deployed VC
Y Combinator
Ekistic Ventures
DCVC
The Engine
Series A8 investors entered at this stage
Thursday Ventures
Anne Wojcicki
Plum Alley
Tom Knight
American Family Institute
Valor Equity Partners
Hyperplane VC
Atreides Management
Other known investors2 additional known investors
Half Court VC
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biobot Analytics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biobot Analytics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







